Drugs Made In America Acquisition Corp. (DMAAR) — SEC Filings
Drugs Made In America Acquisition Corp. (DMAAR) — 15 SEC filings. Latest: 10-Q (Nov 18, 2025). Includes 6 S-1/A, 4 8-K, 3 10-Q.
View Drugs Made In America Acquisition Corp. on SEC EDGAR
Overview
Drugs Made In America Acquisition Corp. (DMAAR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 18, 2025: Drugs Made In America Acquisition Corp. (DMAAR) reported a net income of $5,727,685 for the nine months ended September 30, 2025, a significant turnaround from a net loss of $199,859 for the period from inception (May 23, 2024) through September 30, 2024. This positive shift was primarily driven by
Sentiment Summary
Across 15 filings, the sentiment breakdown is: 1 bullish, 14 neutral. The dominant filing sentiment for Drugs Made In America Acquisition Corp. is neutral.
Filing Type Overview
Drugs Made In America Acquisition Corp. (DMAAR) has filed 3 10-Q, 1 10-K, 4 8-K, 6 S-1/A, 1 S-1 with the SEC between Aug 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (15)
Risk Profile
Risk Assessment: Of DMAAR's 15 recent filings, 0 were flagged as high-risk, 9 as medium-risk, and 6 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | $5,727,685 |
| EPS | $0.19 |
| Debt-to-Equity | N/A |
| Cash Position | $237,604,232 |
| Operating Margin | N/A |
| Total Assets | $237,632,428 |
| Total Debt | $7,356,611 |
Key Executives
- Lynn Stockwell
Industry Context
Drugs Made In America Acquisition Corp. operates within the dynamic pharmaceutical and biotechnology sector, characterized by rapid innovation, significant R&D investment, and stringent regulatory oversight. The industry is driven by the pursuit of novel therapies and treatments for unmet medical needs. Companies in this space face intense competition from established pharmaceutical giants, emerging biotech firms, and academic research institutions, all vying for market share and scientific breakthroughs.
Top Tags
spac (7) · sec-filing (6) · amendment (4) · registration-statement (3) · 10-Q (2) · quarterly-report (2) · filing (2) · SPAC (1) · Pharmaceutical Industry (1) · 10-Q Filing (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $5.7M | For the nine months ended September 30, 2025, a significant increase from a $199,859 loss in the prior period. |
| Cash and investments in Trust Account | $237.6M | As of September 30, 2025, representing the primary asset base for a business combination. |
| Interest earned on Trust Account | $6.45M | For the nine months ended September 30, 2025, driving the company's profitability. |
| Deferred underwriting fee payable | $6.9M | A significant liability contingent on completing a business combination. |
| Redeemable ordinary shares outstanding | 23M | As of September 30, 2025, with a redemption value of $10.33 per share. |
| Basic and diluted net income per redeemable ordinary share | $0.19 | For the nine months ended September 30, 2025, reflecting the interest income. |
| Business Combination Deadline | April 29, 2026 | Initial deadline, with potential extensions up to 21 months total. |
| Share subscription receivable | $608,822 | Amount owed by the Sponsor as of September 30, 2025. |
| SEC File Number | 001-42467 | Identifies the company's filings with the SEC |
| Quarter End Date | March 31, 2025 | Marks the end of the reporting period for this 10-Q. |
| Filing Date | May 20, 2025 | The date the report was officially submitted to the SEC. |
| Fiscal Year End | 2024 | The period covered by the 10-K filing. |
| I.R.S. Employer Identification No. | 99-2394788 | Company's tax identification number. |
| Film Number | 25588360 | Internal SEC processing number for the filing. |
| SIC Code | 6770 | Classifies the company under 'BLANK CHECKS'. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Drugs Made In America Acquisition Corp. (DMAAR)?
Drugs Made In America Acquisition Corp. has 15 recent SEC filings from Aug 2024 to Nov 2025, including 6 S-1/A, 4 8-K, 3 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of DMAAR filings?
Across 15 filings, the sentiment breakdown is: 1 bullish, 14 neutral. The dominant sentiment is neutral.
Where can I find Drugs Made In America Acquisition Corp. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Drugs Made In America Acquisition Corp. (DMAAR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Drugs Made In America Acquisition Corp.?
Key financial highlights from Drugs Made In America Acquisition Corp.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for DMAAR?
The investment thesis for DMAAR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Drugs Made In America Acquisition Corp.?
Key executives identified across Drugs Made In America Acquisition Corp.'s filings include Lynn Stockwell.
What are the main risk factors for Drugs Made In America Acquisition Corp. stock?
Of DMAAR's 15 assessed filings, 0 were flagged high-risk, 9 medium-risk, and 6 low-risk.
What are recent predictions and forward guidance from Drugs Made In America Acquisition Corp.?
Forward guidance and predictions for Drugs Made In America Acquisition Corp. are extracted from SEC filings as they are enriched.